A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Myelodysplastic Syndromes
DRUG: Luspatercept
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, through study completion; an average 1 year.
Objectives:

Primary Objectives:

* To assess the clinical activity and safety of luspatercept in patients with transfusion independent lower risk MDS
* To assess the clinical activity and safety of luspatercept in patients with transfusion dependent lower risk MDS
* To study the effects on hematopoeisis of luspatercept in patients treated on this study

Secondary Objectives:

* To assess the duration of response of patients with treated with luspatercept in this study
* To assess the overall survival and time to transformation of patients with treated with luspatercept in this study
* To assess transfusion free survival period in patients that were transfusion independent treated with luspatercept in this study
* To measure trends in neutrophil and platelet counts in patients treated in this study